{"id":"NCT00576251","sponsor":"Alcon Research","briefTitle":"TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10","primaryCompletion":"2008-02","completion":"2008-03","firstPosted":"2007-12-19","resultsPosted":"2010-01-14","lastUpdate":"2010-03-02"},"enrollment":221,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Ocular Inflammation Associated With Blepharaconjunctivitis"],"interventions":[{"type":"DRUG","name":"Tobramycin 0.3%/Dexamethasone 0.05%","otherNames":[]},{"type":"DRUG","name":"TOBRADEX","otherNames":[]}],"arms":[{"label":"Tobramycin 0.3%/Dexamethasone 0.05%","type":"EXPERIMENTAL"},{"label":"TOBRADEX","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to describe the differences in efficacy between TOBRADEX Ophthalmic Suspension and Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension in the treatment of ocular inflammation and infection associated with blepharaconjunctivitis","primaryOutcome":{"measure":"Percent of Patients Who Display Microbiological Success (Eradication of Baseline Pathogens at Day 4)","timeFrame":"Day 4 - Test Of Cure (TOC) compared to Day 0","effectByArm":[{"arm":"Tobramycin 0.3%/Dexamethasone 0.05%","deltaMin":100,"sd":null},{"arm":"TOBRADEX Ophthalmic Suspension","deltaMin":94.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":109},"commonTop":[]}}